![REGENXBIO Inc](/common/images/company/N_RGNX.png)
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neur... Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). Show more
REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025 PR Newswire ROCKVILLE, Md., Jan. 30, 2025 ROCKVILLE, Md., Jan. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:...
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases PR Newswire ROCKVILLE, Md., Jan. 14, 2025 REGENXBIO to receive $110...
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program PR Newswire NORTH CHICAGO, Ill. and ROCKVILLE, Md., Jan. 13, 2025 Pivotal data evaluating the safety and efficacy of the...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.62 | 7.79874213836 | 7.95 | 8.7451 | 7.51 | 876663 | 8.16883535 | CS |
4 | 0.57 | 7.125 | 8 | 8.7451 | 6.56 | 1042476 | 7.55170539 | CS |
12 | -2.99 | -25.8650519031 | 11.56 | 11.63 | 6.56 | 1367430 | 8.30849955 | CS |
26 | -4.54 | -34.6300533944 | 13.11 | 13.48 | 6.56 | 881339 | 9.17437797 | CS |
52 | -4.94 | -36.5655070318 | 13.51 | 28.8 | 6.56 | 764506 | 12.41691956 | CS |
156 | -17.85 | -67.5624526874 | 26.42 | 35.73 | 6.56 | 529163 | 17.28257056 | CS |
260 | -41.01 | -82.7148043566 | 49.58 | 54.97 | 6.56 | 480303 | 23.83842254 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales